d'Adhemar, Charles J <br/><br/>
The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.  [electronic resource] 

 -  PloS one  2014 
 - e100816 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0100816  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents, Phytogenic--pharmacology<br/>Carcinoma, Ovarian Epithelial<br/>Cell Line, Tumor<br/>Cystadenocarcinoma, Serous--diagnosis<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Genotype<br/>Humans<br/>Immunohistochemistry<br/>MicroRNAs--genetics<br/>Middle Aged<br/>Myeloid Differentiation Factor 88--genetics<br/>Neoplasms, Glandular and Epithelial--diagnosis<br/>Neoplastic Stem Cells--drug effects<br/>Ovarian Neoplasms--diagnosis<br/>Paclitaxel--pharmacology<br/>Phenotype<br/>Prognosis<br/>RNA, Small Interfering--genetics<br/>Signal Transduction<br/>Survival Analysis<br/>Toll-Like Receptor 4--antagonists & inhibitors